RXi Pharmaceuticals Corporation RXII today announced the pharmacokinetic results of their
single dose Phase 1 study with RXI-109 in healthy subjects. This drug
candidate is a highly selective CTGF targeting sd-rxRNA® compound that
is administered through intradermal injections to prevent or
reduce dermal scarring following surgery or trauma, as well as for the
management of hypertrophic scars and keloids.
In this study, 15 volunteers divided over 5 cohorts received single
intradermal injections in a dose escalating manner, and blood was drawn
at various time points to evaluate the distribution of the drug beyond
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in